期刊
ENDOCRINE-RELATED CANCER
卷 22, 期 6, 页码 T209-T220出版社
BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-15-0217
关键词
androgen receptor; prostate cancer; cancer stem cells; prostate cancer stem cells; castration-resistant prostate cancer
资金
- NIH [NCI R01-CA155693]
- DOD [W81XWH-13-1-0352, W81XWH-14-1-0575]
- CPRIT [RP120380]
- MDACC Center for Cancer Epigenetics
Prostate cancer (PCa) contains phenotypically and functionally distinct cells, and this cellular heterogeneity poses clinical challenges as the distinct cell types likely respond differently to various therapies. Clonal evolution, driven by genetic instability, and intraclonal cancer cell diversification, driven by cancer stem cells (CSCs), together create tumor cell heterogeneity. In this review, we first discuss PCa stem cells (PCSCs) and heterogeneity of androgen receptor (AR) expression in primary, metastatic, and treatment-failed PCa. Based on literature reports and our own studies, we hypothesize that, whereas PCSCs in primary and untreated tumors and models are mainly AR(-), PCSCs in CRPCs could be either AR(+) or AR(-/lo). We illustrate the potential mechanisms AR(+) and AR(-) PCSCs may employ to propagate PCa at the population level, mediate therapy resistance, and metastasize. As a result, targeting AR alone may not achieve long-lasting therapeutic efficacy. Elucidating the roles of AR and PCSCs should provide important clues to designing novel personalized combinatorial therapeutic protocols targeting both AR(+) and AR(-) PCa cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据